PeptideJournal
Peptide Profiles25 min read

GHRP-2: Growth Hormone Releasing Peptide Profile

In the pursuit of optimizing growth hormone levels without synthetic GH replacement, researchers developed a class of synthetic peptides that work with the body's natural systems rather than override them.

In the pursuit of optimizing growth hormone levels without synthetic GH replacement, researchers developed a class of synthetic peptides that work with the body's natural systems rather than override them. GHRP-2, also known by its pharmaceutical name pralmorelin, stands out as one of the most potent compounds in this family. This hexapeptide mimics ghrelin—the naturally occurring "hunger hormone"—to trigger growth hormone release from the pituitary gland.

Unlike direct growth hormone administration, which suppresses natural production, GHRP-2 preserves the body's pulsatile secretion pattern. This distinction matters. The peptide binds to growth hormone secretagogue receptors in both the hypothalamus and pituitary, initiating a cascade that results in significantly elevated GH levels. Clinical studies demonstrate impressive results: in one trial, GHRP-2 infusion increased serum GH levels more than 13-fold compared to saline controls.

But GHRP-2's story extends beyond laboratory efficacy. Kaken Pharmaceutical brought it to market in Japan in 2004 as GHRP Kaken 100, where it serves as a diagnostic tool for assessing growth hormone deficiency in both adults and children. This regulatory approval provides real-world validation of the peptide's reliability and safety profile. For researchers, clinicians, and those exploring peptide therapeutics, understanding GHRP-2 means understanding how selective receptor activation can influence complex endocrine systems.

Table of Contents

Quick Facts

PropertyDetails
Full NamePralmorelin (GHRP-2)
Other NamesKP-102, GPA-748, WAY-GPA-748, growth hormone releasing peptide-2
ClassificationSynthetic hexapeptide growth hormone secretagogue
Amino Acid SequenceD-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂
Molecular Weight~818 Da
FormulaC₄₅H₅₅N₉O₆
Primary ReceptorGrowth hormone secretagogue receptor 1a (GHS-R1a) / Ghrelin receptor
Half-LifeApproximately 30 minutes (0.55 ± 0.14 hours)
Peak Concentration15-60 minutes post-administration
FDA StatusNot approved in the United States
Japan Regulatory StatusApproved by PMDA (October 2004) as diagnostic agent
Brand Name (Japan)GHRP Kaken 100
ManufacturerKaken Pharmaceutical (Japan)

What Is GHRP-2?

GHRP-2 belongs to a family of synthetic peptides engineered to stimulate growth hormone release through mechanisms distinct from growth hormone-releasing hormone (GHRH). While GHRH was identified in the 1980s, researchers continued searching for compounds that could amplify GH secretion through alternative pathways. This search led to the development of growth hormone-releasing peptides (GHRPs), beginning with GHRP-6 and evolving to include more potent analogs like GHRP-2.

The peptide's structure consists of six amino acids, several of which are D-amino acids—unnatural mirror images of the L-amino acids found in proteins. This modification provides resistance to enzymatic breakdown, extending the peptide's activity window. The sequence incorporates a naphthylalanine residue, a synthetic amino acid that enhances binding affinity to the target receptor.

Development History

GHRP-2 emerged from systematic modifications of met-enkephalin, an endogenous opioid peptide. Through iterative structural changes, researchers at Kaken Pharmaceutical developed KP-102 (the research designation for GHRP-2), which demonstrated potent GH-releasing activity without the opioid effects of its parent compound. The development process focused on maximizing growth hormone secretagogue activity while minimizing off-target effects.

The peptide underwent extensive preclinical testing in the 1990s before advancing to human trials. Studies in children with short stature showed that intranasal administration could improve growth velocity, though the effects were modest. More compelling data emerged from diagnostic testing, where GHRP-2 proved as reliable as GHRH in assessing pituitary GH reserve. This led to its 2004 approval in Japan specifically as a diagnostic agent for growth hormone deficiency.

Classification and Relationship to Ghrelin

In 1999, Japanese researchers discovered ghrelin, the endogenous ligand for the "GH secretagogue receptor" that GHRPs had been activating. This discovery recontextualized the GHRPs: they were ghrelin mimetics, synthetic agonists of a natural system that links appetite, metabolism, and growth hormone secretion. GHRP-2 binds to the GHS-R1a receptor, the same receptor ghrelin activates, triggering many of the same downstream effects including hunger stimulation and GH release.

This connection to ghrelin explains GHRP-2's appetite-enhancing properties. While some growth hormone secretagogues like ipamorelin show minimal impact on hunger, GHRP-2 significantly increases food intake—a predictable result of strong ghrelin receptor activation.

How GHRP-2 Works: Mechanisms of Action

GHRP-2's activity centers on the growth hormone secretagogue receptor 1a (GHS-R1a), a G protein-coupled receptor located in the hypothalamus and pituitary gland. When GHRP-2 binds to this receptor, it initiates a cascade of intracellular signaling events that culminate in growth hormone release. The process operates through dual mechanisms, acting at both the pituitary level and the hypothalamic level.

Direct Pituitary Stimulation

At the pituitary, GHRP-2 binds directly to GHS-R1a receptors on somatotroph cells—the specialized cells that synthesize and store growth hormone. This binding activates intracellular signaling pathways, primarily through protein kinase C (PKC) and calcium influx mechanisms. Research in bovine pituitary cells demonstrated that GHRP-2 stimulates GH secretion through Ca²⁺ influx via voltage-gated calcium channels, distinct from the cAMP-dependent pathway that GHRH uses.

The calcium-dependent mechanism means GHRP-2 works through a different molecular pathway than sermorelin and other GHRH analogs. This explains why combining GHRP-2 with GHRH produces synergistic effects: the two compounds activate complementary pathways that converge on growth hormone release.

Hypothalamic Action

Beyond direct pituitary effects, GHRP-2 acts on the hypothalamus to increase secretion of growth hormone-releasing hormone. The hypothalamus contains high concentrations of GHS-R1a receptors, and GHRP-2 activation at this level promotes GHRH release, which then travels to the pituitary to further stimulate GH secretion. This dual-level action amplifies the overall effect beyond what either mechanism would produce alone.

Additionally, GHRP-2 may reduce somatostatin tone—somatostatin being the hormone that inhibits GH release. By suppressing this natural brake on GH secretion, GHRP-2 creates a more favorable environment for growth hormone release.

Receptor Pharmacology

The GHS-R1a receptor exhibits one of the highest constitutive activity levels among G protein-coupled receptors, meaning it signals even without a ligand bound. Ghrelin and GHRP-2 enhance this signaling to about 50% above basal levels. This high constitutive activity suggests that the ghrelin system maintains a constant low-level drive on growth hormone secretion, which GHRP-2 amplifies.

GHRP-2 demonstrates high binding affinity for GHS-R1a compared to some other GHRPs. In comparative studies, GHRP-2 showed higher potency than GHRP-6 (requiring lower doses to achieve similar effects) though maximum efficacy was slightly lower.

Effects on Other Hormones

Unlike selective growth hormone secretagogues such as ipamorelin, GHRP-2 modestly elevates ACTH and cortisol levels. Research shows that GHRP-2 stimulates ACTH and cortisol to approximately the same extent as human corticotropin-releasing hormone (hCRH). The mechanism appears to involve release of CRH from the hypothalamus, which then drives ACTH secretion from the pituitary.

Prolactin also shows a transient increase following GHRP-2 administration, though the response is considerably milder than that produced by thyrotropin-releasing hormone (TRH), a dedicated prolactin secretagogue. Prolactin levels typically return to baseline within 60 minutes.

Pulsatile Secretion Preservation

A critical advantage of GHRP-2 over synthetic growth hormone replacement is preservation of pulsatile secretion. Natural GH release occurs in pulses, with the largest pulses typically occurring during deep sleep. GHRP-2 enhances these pulses rather than replacing them with continuous elevation. This pattern more closely mimics physiological GH secretion and may reduce the risk of negative feedback suppression that occurs with exogenous GH administration.

Research Evidence

GHRP-2 has been studied across multiple contexts, from diagnostic testing to therapeutic applications in growth disorders, metabolic conditions, and body composition optimization. The breadth of research spans pediatric populations, healthy adults, and patients with specific endocrine conditions.

Growth Hormone Stimulation in Healthy Adults

A controlled study by Laferrère et al. examined GHRP-2's effects in seven lean, healthy males. Subjects received continuous subcutaneous infusion of GHRP-2 (1 μg/kg/h) or saline for 270 minutes. During GHRP-2 infusion, serum GH levels rose dramatically, with area under the curve (AUC) of 5,550 ± 1,090 μg/L/240 min compared to 412 ± 161 μg/L/240 min with saline (p = 0.003)—a more than 13-fold increase.

Notably, GHRP-2 infusion increased food intake by 35.9 ± 10.9% compared to saline, confirming that the peptide replicates ghrelin's appetite-stimulating effects in humans. This appetite enhancement distinguishes GHRP-2 from more selective compounds like ipamorelin.

Pediatric Studies: Growth Effects

Pihoker et al. conducted a study administering intranasal GHRP-2 to children with short stature. Subjects received 5-15 μg/kg twice daily for three months, then three times daily. Height velocity increased from 3.7 ± 0.2 cm/year at baseline to 6.1 ± 0.3 cm/year at six months, and maintained at 6.0 ± 0.4 cm/year through 18-24 months. While modest, this improvement demonstrated that chronic GHRP-2 administration could influence linear growth in children with impaired growth hormone secretion.

The same research group compared GHRP-2 with GHRH for diagnostic purposes. GH responses to both peptides were similar in each child, and both proved equally reliable in predicting pituitary reserve. This equivalence supported GHRP-2's use as an alternative diagnostic agent.

Pharmacokinetic Studies

Kopchick et al. conducted a Phase I pharmacokinetic study in children, administering GHRP-2 intravenously at 1 μg/kg. The peptide followed two-compartment kinetics with a terminal half-life of 0.55 ± 0.14 hours (approximately 33 minutes). Peak plasma concentrations averaged 7.4 ± 3.8 ng/mL, with an AUC of 2.02 ± 1.37 ng/mL·h. Plasma clearance was 0.66 ± 0.32 L/h·kg with an apparent volume of distribution of 0.32 ± 0.14 L/kg.

These pharmacokinetic parameters explain the clinical practice of administering GHRP-2 multiple times daily. The short half-life means effects are transient, requiring repeated dosing to maintain elevated GH levels throughout the day or to time GH pulses strategically around training, meals, or sleep.

GH Deficiency and Diagnostic Applications

Multiple studies established GHRP-2's reliability as a diagnostic tool for growth hormone deficiency. Popovic et al. demonstrated that GHRP-2 could stimulate GH release even in patients with mutated GHRH receptors who were unresponsive to GHRH itself. This finding proved that GHRP-2 works through a GHRH-independent mechanism, making it valuable for diagnosing different types of GH deficiency.

The Japanese regulatory approval as GHRP Kaken 100 established a cut-off threshold GH peak of 15.0 μg/L for distinguishing patients with GH deficiency from healthy controls. This standardized threshold enables clinicians to use GHRP-2 stimulation tests for objective diagnosis.

Metabolic and Body Composition Effects

Research in various animal models demonstrated GHRP-2's effects on body composition, fat metabolism, and muscle growth. Studies in swine showed that GHRP-2 administration increased GH release with an ED50 of 0.6 nmol/kg, though maximum efficacy (Emax = 56 ± 6 ng GH/mL plasma) was lower than that of some other GHRPs.

In a case study, one year of intranasal GHRP-2 application improved body weight and resolved hypoglycemia in a severely emaciated anorexia nervosa patient. The patient experienced increased hunger and food intake, decreased early satiety, and gradual weight gain—effects directly attributable to GHRP-2's ghrelin-mimetic properties.

Synergy with GHRH

Research consistently demonstrates that combining GHRP-2 with GHRH produces greater GH release than either compound alone. This synergy results from their complementary mechanisms: GHRH activates adenylyl cyclase and increases cAMP, while GHRP-2 works through PKC and calcium signaling. The convergence of these pathways on GH release produces additive or synergistic effects.

Cordido et al. found that combining CJC-1295 (a GHRH analog) with GHRP-2 maintained robust GH secretion even in young men with experimentally induced hypogonadism, indicating that this combination resists suppression from sex hormone deficiency.

Hormonal Side Effects

Multiple studies characterized GHRP-2's effects on hormones beyond growth hormone. Arvat et al. compared GHRP-2 and hexarelin with GHRH, TRH, and hCRH. Both GHRP-2 and hexarelin produced slight but significant increases in prolactin, ACTH, and cortisol. The ACTH/cortisol-releasing activity was similar to that of hCRH, suggesting meaningful activation of the hypothalamic-pituitary-adrenal (HPA) axis.

This effect distinguishes GHRP-2 from ipamorelin, which shows minimal ACTH/cortisol elevation even at doses 200-fold higher than the ED50 for GH release. For applications where selective GH stimulation without stress hormone activation is desired, ipamorelin holds an advantage. However, for diagnostic purposes or when robust GH release is the priority, GHRP-2's broader endocrine effects may be acceptable.

Comparison With Other GHRPs

The growth hormone releasing peptide family includes several synthetic analogs, each with distinct pharmacological profiles. Understanding these differences helps clarify GHRP-2's position within the class.

GHRP-2 vs GHRP-6

GHRP-6 was the first hexapeptide GHRP developed and served as the template for subsequent analogs. Comparative studies show that GHRP-2 exhibits higher potency than GHRP-6—requiring lower doses to achieve similar GH release. In swine studies, GHRP-2 had an ED50 of 0.6 nmol/kg compared to GHRP-6's 2.3 nmol/kg.

However, GHRP-6 demonstrated slightly higher maximum efficacy (Emax = 65 ng GH/mL vs 56 ng GH/mL for GHRP-2), meaning that at maximum doses, GHRP-6 produced marginally higher peak GH levels. Both peptides significantly stimulate appetite through ghrelin receptor activation, with GHRP-6 generally considered to have the strongest hunger-inducing effects in the GHRP family.

Research into intracellular signaling revealed mechanistic differences: GHRP-6 does not increase cAMP levels in ovine pituitary cells, while GHRP-2 produces modest cAMP elevation alongside its primary PKC-mediated effects. This suggests GHRP-2 may have slightly broader receptor coupling than GHRP-6, though both primarily work through calcium and PKC pathways.

GHRP-2 vs Ipamorelin

Ipamorelin represents a more refined development in the GHRP family, designed for selective GH release with minimal effects on other pituitary hormones. The most significant difference lies in hormonal selectivity: ipamorelin does not significantly elevate ACTH or cortisol even at doses exceeding 200 times the ED50 for GH release, whereas GHRP-2 modestly increases both hormones.

In terms of GH-releasing potency, GHRP-2 requires lower doses than ipamorelin (ED50 0.6 nmol/kg vs 2.3 nmol/kg), but ipamorelin achieves higher maximum efficacy similar to GHRP-6. Ipamorelin also demonstrates a longer duration of action with systemic plasma clearance approximately five-fold lower than GHRP-6, suggesting improved pharmacokinetic properties.

Appetite stimulation differs markedly: GHRP-2 substantially increases hunger and food intake through strong ghrelin receptor activation, while ipamorelin produces minimal appetite effects. This makes ipamorelin preferable for body recomposition goals where calorie control matters, while GHRP-2's appetite stimulation may benefit those struggling to maintain adequate food intake.

For therapeutic or research applications prioritizing selective GH elevation without HPA axis activation, ipamorelin holds clear advantages. GHRP-2's broader endocrine effects may be acceptable in diagnostic contexts or when robust, multi-hormonal responses are tolerable.

GHRP-2 vs Hexarelin

Hexarelin represents one of the most potent GHRPs developed. Comparative studies by Arvat et al. found that GHRP-2 and hexarelin have similar, dose- and age-dependent effects on GH secretion, both releasing more GH than GHRH. The peptides show equivalent effects on prolactin, ACTH, and cortisol, with both stimulating these hormones to similar extents.

Research identified a key difference in cardiac receptor binding: hexarelin binds with high affinity to CD36, a scavenger receptor expressed in cardiac tissue, while GHRP-2's affinity for CD36 is lower. This CD36 binding underlies hexarelin's cardiovascular effects, including improvement of cardiac function in animal models. GHRP-2 demonstrates some cardioprotective properties but to a lesser degree than hexarelin.

Both peptides exhibit cytoprotective effects across multiple tissue types, decreasing reactive oxygen species, enhancing antioxidant defenses, and reducing inflammation. These properties have been demonstrated in cardiac, neuronal, gastrointestinal, and hepatic cells.

GHRP-2 vs GHRH Analogs (Sermorelin, CJC-1295, Tesamorelin)

GHRH analogs like sermorelin, CJC-1295, and tesamorelin work through the GHRH receptor rather than the ghrelin receptor. This fundamental mechanistic difference creates complementary pharmacology: GHRH analogs increase cAMP and activate the cAMP/PKA pathway, while GHRP-2 works through calcium and PKC signaling.

Because these mechanisms converge on GH release, combining GHRH analogs with GHRP-2 produces synergistic effects. Research demonstrates that L-arginine plus GHRH or L-arginine plus GHRP-2 maintain robust GH secretion even in hypogonadal states, indicating resilience against conditions that suppress GH.

From a regulatory perspective, tesamorelin is FDA-approved for HIV-associated lipodystrophy, providing a prescription pathway for GHRH-based therapy. GHRP-2, approved only in Japan as a diagnostic agent, lacks FDA approval for therapeutic use.

GHRP-2 vs Non-Peptide Secretagogues (MK-677)

MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue that binds to the same GHS-R1a receptor as GHRP-2. The primary advantage of MK-677 is oral bioavailability and a much longer half-life (approximately 24 hours), allowing once-daily dosing.

Both compounds elevate ghrelin-like signaling and increase appetite. MK-677's prolonged action maintains elevated GH and IGF-1 levels throughout the day, while GHRP-2's short half-life produces more pulsatile effects that may better mimic natural GH secretion patterns. Some researchers argue that pulsatile GH release is more physiological and may reduce the risk of negative feedback compared to sustained elevation.

The longer duration of MK-677 makes it more practical for oral self-administration, while GHRP-2 requires subcutaneous or intranasal administration multiple times daily. For research applications requiring precise timing of GH pulses, GHRP-2's short half-life offers controllability that MK-677 lacks.

Safety Profile and Side Effects

GHRP-2 has undergone extensive evaluation in both research and clinical diagnostic settings. The safety profile reflects its mechanism as a ghrelin receptor agonist with additional effects on ACTH and cortisol secretion.

Common Side Effects

The most frequently reported side effect is increased appetite. Clinical studies document food intake increases of approximately 36% during GHRP-2 administration. This effect results directly from ghrelin receptor activation in hypothalamic feeding centers. For individuals using GHRP-2 as an appetite stimulant (such as in cachexia or eating disorders), this represents a therapeutic effect. For those focused on body composition goals requiring calorie control, the hunger increase may be undesirable.

Transient effects associated with growth hormone elevation include flushing, increased body temperature, and sweating. These typically occur within minutes of administration and resolve within 30-60 minutes as GHRP-2 levels decline.

Injection site reactions—redness, itching, pain, or small lumps—can occur with subcutaneous or intramuscular administration. These are generally mild and resolve spontaneously. Proper injection technique and site rotation minimize these reactions.

Effects associated with elevated growth hormone and IGF-1 may develop with prolonged use:

Water retention (edema) particularly in the hands, feet, and face, occurs because growth hormone promotes sodium and water retention in the kidneys. This effect is generally mild with GHRP-2 due to its pulsatile action, but some individuals experience noticeable swelling.

Joint pain (arthralgias) and stiffness can develop, potentially reflecting increased soft tissue growth around joints or reactivation of growth in cartilage. Individuals with pre-existing arthritis may experience exacerbation of symptoms.

Carpal tunnel syndrome has been reported with long-term growth hormone elevation. The mechanism involves soft tissue proliferation in the wrist compressing the median nerve. Symptoms include numbness, tingling, or pain in the thumb, index, and middle fingers.

Metabolic Effects

GHRP-2 may reduce insulin sensitivity, as growth hormone antagonizes insulin action. In healthy individuals with normal pancreatic function, this typically results in compensatory insulin secretion that maintains normal glucose levels. However, individuals with impaired glucose tolerance or diabetes should monitor blood sugar carefully.

Some studies show transient increases in blood glucose following GHRP-2 administration, though glucose typically returns to baseline as GH levels decline. The clinical significance of these transient increases remains unclear, particularly with the pulsatile dosing pattern used with GHRP-2.

HPA Axis Effects

GHRP-2 modestly elevates ACTH and cortisol to levels comparable with corticotropin-releasing hormone administration. These increases are transient, with hormones returning to baseline within approximately 60 minutes. However, repeated daily administration may result in cumulative effects on the HPA axis.

Chronic cortisol elevation, even if mild, can produce effects including increased central fat deposition, insulin resistance, immune suppression, and altered mood. The clinical significance of GHRP-2's cortisol effects remains debated, with some researchers arguing that the brief, pulsatile elevation differs substantially from sustained hypercortisolism.

Prolactin Effects

Prolactin shows modest, transient increases following GHRP-2 administration, returning to baseline within 60 minutes. In men, chronically elevated prolactin can reduce testosterone production and libido and may cause gynecomastia (breast tissue development). The brief prolactin spike with GHRP-2 appears unlikely to produce these effects with typical usage patterns, though individuals with pre-existing hyperprolactinemia should exercise caution.

Clinical Trial Safety Data

An eight-month clinical trial in growth hormone-deficient children using intranasal GHRP-2 reported no side effects or toxicities. Similarly, studies involving subcutaneous infusion for 270 minutes in healthy adults reported no adverse events requiring intervention.

The safety advantages of GHRP-2 relative to synthetic growth hormone include preservation of endogenous synthesis, pulsatile secretion patterns, and automatic regulation through negative feedback. Because GHRP-2 stimulates natural GH production rather than replacing it, the body's regulatory mechanisms remain functional, potentially reducing risks of overdose or excessive GH elevation.

Contraindications and Precautions

GHRP-2 is contraindicated in individuals with:

  • Active malignancy, as growth hormone and IGF-1 may promote tumor growth
  • Diabetic retinopathy, which may worsen with GH/IGF-1 elevation
  • Acute critical illness following open heart surgery, abdominal surgery, or multiple trauma, where elevated GH has been associated with increased mortality

Caution is warranted in:

  • Diabetes or impaired glucose tolerance
  • Pre-existing arthritis or joint disorders
  • History of carpal tunnel syndrome
  • Conditions associated with elevated prolactin
  • Individuals with risk factors for cardiovascular disease, as growth hormone affects cardiac structure and function

Drug Interactions

GHRP-2's effects on glucose metabolism may interact with diabetes medications, potentially requiring dose adjustments. The peptide's effects on cortisol may interact with medications affecting the HPA axis. Growth hormone can alter the metabolism of various drugs, including glucocorticoids, sex steroids, and thyroid hormones.

The regulatory landscape for GHRP-2 varies dramatically by jurisdiction, with approved medical use in Japan contrasting sharply with the compound's unapproved status in most other countries.

Japan: Approved Diagnostic Agent

GHRP-2 received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in October 2004. Marketed by Kaken Pharmaceutical as GHRP Kaken 100, it is indicated for diagnostic assessment of growth hormone deficiency in adults and children over four years of age. This represents the only approved medical use of GHRP-2 anywhere in the world.

The diagnostic protocol involves administering GHRP-2 and measuring the resulting GH response. A peak GH concentration below 15.0 μg/L indicates growth hormone deficiency, while levels above this threshold suggest adequate pituitary GH reserve. This standardized test provides an objective method for diagnosing GH deficiency independent of GHRH responsiveness.

United States: Not FDA Approved

GHRP-2 has never been approved by the U.S. Food and Drug Administration for any indication. The compound underwent clinical development by Wyeth (which licensed it from Kaken Pharmaceutical for the U.S. and Canadian markets), but no New Drug Application was submitted for therapeutic use.

From a regulatory perspective, GHRP-2 does not meet the criteria for legal compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Specifically, GHRP-2:

  • Is not the subject of a USP or NF monograph
  • Is not a component of an FDA-approved drug
  • Does not appear on the FDA's 503A bulk substances list

The FDA has issued multiple warning letters to compounding pharmacies producing GHRP-2, stating that products compounded with this substance do not qualify for exemptions from FDA approval requirements, adequate labeling requirements, or current Good Manufacturing Practice (CGMP) compliance. These warning letters make clear the FDA's position that compounding GHRP-2 violates federal law.

Practical Implications for Compounding

Some patients and clinicians have sought GHRP-2 through compounding pharmacies, operating under the assumption that peptides exist in a regulatory "gray zone." This assumption is incorrect. The FDA explicitly stated in multiple enforcement actions that GHRP-2 cannot be lawfully compounded because it fails to meet the statutory requirements.

Pharmacies that compound GHRP-2 face potential enforcement action including warning letters, consent decrees, injunctions, and criminal prosecution. Physicians who prescribe compounded GHRP-2 should be aware that they are prescribing an unapproved drug that does not qualify for compounding exemptions.

Research Use

GHRP-2 remains available from peptide synthesis companies for research purposes. These suppliers market the peptide explicitly as a research chemical "not for human consumption." This designation allows distribution for legitimate scientific research but does not provide a legal pathway for clinical use.

Institutional review boards (IRBs) may approve clinical research protocols involving GHRP-2, provided the research meets ethical standards and regulatory requirements for investigational new drugs. Such research would typically require an IND application to the FDA.

International Status

Outside Japan and the United States, GHRP-2's regulatory status varies. Most countries do not have approved GHRP-2 products. In jurisdictions with less stringent pharmaceutical regulations, GHRP-2 may be available through compounding pharmacies or as an unregistered import, though the legality and safety of such products remain questionable.

The World Anti-Doping Agency (WADA) prohibits growth hormone secretagogues including GHRP-2 for competitive athletes. Detection methods exist for identifying GHRP metabolites in urine, making use of these compounds a doping violation that can result in competition bans.

Comparison With Approved Alternatives

For clinicians and patients seeking legal, approved options for growth hormone augmentation, several alternatives exist:

  • Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy
  • Sermorelin was previously available as an approved drug (Geref) though it was discontinued; compounding may be possible in some cases
  • Semaglutide and other GLP-1 agonists are approved for metabolic indications, though they work through different mechanisms
  • Recombinant human growth hormone itself (somatropin) is approved for multiple indications including GH deficiency, though it carries different risks than GH secretagogues

These approved alternatives provide pathways for patients with legitimate medical needs while avoiding the legal and safety concerns associated with unapproved compounded peptides.

Frequently Asked Questions

What is the difference between GHRP-2 and semaglutide?

GHRP-2 and semaglutide are entirely different peptides that work through unrelated mechanisms. GHRP-2 is a ghrelin receptor agonist that stimulates growth hormone release and increases appetite. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves glucose control. Semaglutide is FDA-approved for diabetes and obesity, while GHRP-2 has no FDA approval. The compounds have opposite effects on hunger: GHRP-2 substantially increases appetite, while semaglutide suppresses it.

How does GHRP-2 compare to ipamorelin for selectivity?

Ipamorelin demonstrates superior selectivity compared to GHRP-2. While both peptides stimulate growth hormone release through the ghrelin receptor, ipamorelin produces minimal effects on ACTH, cortisol, and prolactin even at high doses. GHRP-2 modestly elevates these hormones to levels comparable with corticotropin-releasing hormone. For applications prioritizing selective GH stimulation without HPA axis activation, ipamorelin holds advantages. However, GHRP-2 demonstrates higher potency (lower required doses) and has more extensive clinical validation, including regulatory approval in Japan.

Can GHRP-2 be used with CJC-1295?

Yes, GHRP-2 is frequently combined with CJC-1295 based on their complementary mechanisms. CJC-1295 is a GHRH analog that increases cAMP and activates the PKA pathway, while GHRP-2 works through calcium influx and PKC signaling. These pathways converge on growth hormone release, producing synergistic effects. Clinical research demonstrates that combining GHRH analogs with GHRPs produces greater GH elevation than either compound alone. This combination strategy has been studied extensively and forms the basis for some therapeutic protocols, though it's important to note that neither compound has FDA approval for therapeutic use in the United States.

Does GHRP-2 need to be cycled?

The necessity of cycling GHRP-2 remains debated and lacks definitive clinical evidence. Proponents of cycling argue that continuous use may lead to receptor desensitization, reduced efficacy, or suppression of natural GH pulsatility. However, clinical studies including an eight-month trial in children found sustained effects without apparent tolerance development. The diagnostic use in Japan does not involve cycling, as it is administered as a single-dose test. For therapeutic applications, some practitioners recommend cycling (such as five days on, two days off) to preserve sensitivity, though this represents empirical practice rather than evidence-based protocol.

Clinical studies have used GHRP-2 doses ranging from 0.5 to 2 μg/kg per dose. For a 70 kg individual, this translates to approximately 35-140 μg per dose. Diagnostic testing in Japan uses standardized doses based on body weight. Some research protocols administered doses two to three times daily, typically before meals and at bedtime to coincide with natural GH pulses. However, no FDA-approved dosing guidelines exist for therapeutic use in the United States. The optimal dosing for various goals (GH augmentation, body composition, recovery) remains unclear. Individual response varies considerably, and what constitutes an "optimal" dose depends on the specific objective and individual physiology.

How long does GHRP-2 stay in the system?

GHRP-2 has a half-life of approximately 30 minutes (0.55 hours in pharmacokinetic studies). Peak plasma concentrations occur 15-60 minutes after administration. The peptide follows two-compartment pharmacokinetics, meaning it distributes rapidly from blood into tissues before being eliminated. By four half-lives (approximately two hours), roughly 94% of the dose has been cleared. Growth hormone elevation persists somewhat longer than GHRP-2 itself, with GH levels typically returning toward baseline within three to four hours. This short duration necessitates multiple daily administrations for sustained effects.

Is GHRP-2 detectable in drug tests?

Standard drug screening panels do not test for peptides like GHRP-2. However, specialized testing methods can detect GHRP-2 metabolites in urine. The World Anti-Doping Agency has developed detection protocols for growth hormone releasing peptides, and these methods are used in competitive sports testing. Research shows that GHRP-2 metabolites can be detected in urine for several days following administration. For athletes subject to WADA-code testing, GHRP-2 constitutes a prohibited substance that will result in sanctions if detected.

What are the risks of long-term GHRP-2 use?

Long-term safety data for GHRP-2 remain limited. The longest published human study lasted eight months in children, showing no adverse effects. Theoretical concerns with chronic growth hormone elevation include increased cancer risk (as GH and IGF-1 can promote tumor growth), cardiovascular remodeling, insulin resistance and diabetes development, and skeletal changes including acromegaly features with extreme use. The HPA axis effects—modest but repeated cortisol elevation—could theoretically produce effects similar to chronic stress if sustained long-term. However, GHRP-2's pulsatile action and preservation of natural feedback mechanisms may reduce risks compared to continuous GH administration. Without decade-long safety studies, long-term risks remain uncertain.

The Bottom Line

GHRP-2 occupies a unique position in the landscape of growth hormone secretagogues. As one of the most studied and potent GHRPs, with regulatory approval as a diagnostic agent in Japan, it represents a scientifically validated approach to stimulating endogenous growth hormone release. The peptide works through ghrelin receptor activation to trigger GH secretion from the pituitary while preserving the body's natural pulsatile secretion pattern—a meaningful advantage over synthetic GH replacement.

Clinical research demonstrates robust effects: a greater than 13-fold increase in serum GH levels during infusion, improvements in growth velocity in children with short stature, and reliable diagnostic utility for assessing pituitary GH reserve. The peptide's dual action on both pituitary and hypothalamic sites, working through calcium and PKC pathways distinct from GHRH, explains its potency and its synergy with GHRH analogs like CJC-1295 and sermorelin.

However, GHRP-2's pharmacology extends beyond selective GH stimulation. Unlike ipamorelin, it modestly elevates ACTH, cortisol, and prolactin—effects that may be acceptable in diagnostic contexts but complicate long-term therapeutic use. Its strong ghrelin-mimetic properties produce significant appetite stimulation, beneficial for conditions like cachexia or anorexia but potentially problematic for body composition goals requiring calorie control.

The regulatory picture presents challenges. Outside Japan's approved diagnostic use, GHRP-2 lacks regulatory pathways for legal access in most jurisdictions. In the United States, the FDA has explicitly stated that GHRP-2 cannot be lawfully compounded, issuing enforcement warnings to pharmacies producing the peptide. This regulatory stance creates a disconnect between research interest and practical access, particularly compared to approved alternatives like tesamorelin.

For researchers, GHRP-2 remains a valuable tool for investigating the ghrelin system, growth hormone regulation, and metabolic control. The extensive body of research—spanning pharmacology, clinical efficacy, and safety—provides a solid foundation for understanding how growth hormone secretagogues work and what effects they produce.

For clinicians and patients considering growth hormone augmentation, GHRP-2's unapproved status in most countries necessitates weighing the scientific evidence supporting its efficacy against regulatory and safety considerations. Approved alternatives exist for specific indications, though they may not perfectly replicate GHRP-2's effects. The decision requires careful consideration of medical need, legal status, and the limited long-term safety data available for chronic use.

What remains clear is that GHRP-2 demonstrated an important proof of concept: that synthetic peptides can reliably stimulate endogenous growth hormone release through the ghrelin system, offering effects distinct from both GHRH analogs and synthetic GH. Whether this scientific validation translates to broader clinical utility depends on future research, regulatory developments, and the emergence of potentially improved analogs with more favorable profiles.

This article is for educational purposes only. PeptideJournal.org does not sell peptides, provide medical advice, or recommend the use of any unapproved substances. Always consult a qualified healthcare provider before making decisions about your health.

References

  1. Laferrère B, et al. Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. J Clin Endocrinol Metab. 2005;90(2):611-614. PMC2824650

  2. Pihoker C, et al. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol. 1997;155(1):79-86. PubMed: 9390009

  3. Alba-Roth J, et al. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. Endocrinology. 1997;138(10):4381-4388. PubMed: 9331879

  4. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Peptides. 1997;18(6):885-891. PubMed: 9285939

  5. Kopchick JJ, et al. Pharmacokinetics and Pharmacodynamics of Growth Hormone-Releasing Peptide-2: A Phase I Study in Children. J Clin Endocrinol Metab. 1998;83(4):1168-1172. Oxford Academic

  6. Seoane LM, et al. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Pharmacol Biochem Behav. 2014;124:278-283. PubMed: 24607724

  7. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822

  8. Popovic V, et al. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol Metab. 2001;86(7):3279-3283. PubMed: 11443201

  9. Cordido F, et al. Preservation of GHRH and GHRP-2 Efficacy in Young Men with Experimentally Induced Hypogonadism. Eur J Endocrinol. 2009;161(4):625-630. PMC2772823

  10. Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Endocrinol Diabetes. 2017;10:1179546817694558. PMC5392015

  11. Kaken Pharmaceutical. GHRP Kaken 100 [Package Insert]. Japan PMDA; 2004.

  12. U.S. Food and Drug Administration. Warning Letter to United Pharmacy, February 11, 2019. FDA.gov

  13. Deghenghi R, et al. Growth hormone-releasing peptides: clinical and basic aspects. Acta Paediatr Suppl. 1996;417:8-13. PubMed: 8950613

  14. Holst B, et al. The ghrelin receptors (GHS-R1a and GHS-R1b). Vitamins and Hormones. 2013;92:1-30. PubMed: 23652387

  15. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. Wiley Online Library

  16. Baumann GP, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Test Anal. 2015;7(11-12):950-960. PubMed: 25869809

  17. Nagamine T, et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle. 2016;7(3):361-365. PMC4575555